Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Lung Cancer is Scopus-indexed (Q1, CiteScore 7.4), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Elsevier Ireland Ltd.
Checked against the index lists dated .
ISSN 0169-5002Verify ISSN ↗1872-8332Verify ISSN ↗
Publisher: Elsevier Ireland Ltd
Cost to publish: About US$3,390 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pulmonary and Respiratory Medicine | 23 / 165 | 86th | Q1 |
| Oncology | 78 / 428 | 81st | Q1 |
| Cancer Research | 68 / 233 | 71st | Q2 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1985–present, best quartile Q1, CiteScore 7.4.
Lung Cancer is Q1 in Pulmonary and Respiratory Medicine (rank 23 of 165), Q1 in Oncology (rank 78 of 428) and Q2 in Cancer Research (rank 68 of 233), by CiteScore 2025.
Lung Cancer is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 7.4, which places it in quartile Q1 at the 86th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.928, quartile Q1, with an H-index of 160.
The publisher lists an article processing charge of about US$3,390 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Lung Cancer is published by Elsevier Ireland Ltd. Its print ISSN is 0169-5002 and its online ISSN is 1872-8332.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Lung Cancer has an h-index of 186 and a 2-year mean of 1.64 citations per paper (OpenAlex). Its Scopus CiteScore is 7.4, quartile Q1. On 2-year citations it ranks #68 of 160 Scopus journals in Pulmonary and Respiratory Medicine.
Lung Cancer published 851 papers in 2025. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 100 research articles (2026), authors are most often from China (18.8%), Japan (14.4%) and United States (13.4%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 15 retracted papers are recorded (0.5 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.